Condition: B-cell Acute Lymphoblastic Leukemia · Diffuse Large B-cell Lymphoma · Burkitt Lymphoma · Sponsor: Merck Sharp & Dohme LLC
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Children's Hospital Los Angeles ( Site 1006) | Los Angeles, California, United States | Recruiting |
| Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016) | Aurora, Colorado, United States | Recruiting |
| Yale New Haven Hospital ( Site 1012) | New Haven, Connecticut, United States | Recruiting |
| Johns Hopkins All Children's Hospital ( Site 1025) | St. Petersburg, Florida, United States | Recruiting |
| University of Iowa-Holden Comprehensive Cancer Center ( Site 1017) | Iowa City, Iowa, United States | Recruiting |
| Dana-Farber Cancer Institute ( Site 1013) | Boston, Massachusetts, United States | Recruiting |
| Corewell Health ( Site 1001) | Grand Rapids, Michigan, United States | Recruiting |
| Children's Mercy Hospital ( Site 1024) | Kansas City, Missouri, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey ( Site 1008) | New Brunswick, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center ( Site 1010) | New York, New York, United States | Recruiting |
| New York Medical College ( Site 1023) | Valhalla, New York, United States | Recruiting |
| Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003) | Fargo, North Dakota, United States | Recruiting |
+ 59 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06395103